Man Group’s Biogen BIIB Stock Holding History

Man Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400	Closed	-$84K	–	2069
2022 Q1	$84K	Buy	+400	New	+$87K	﹤0.01%	2075

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group's BIIB Position: Q1 2026 in Review

Man Group reduced its Biogen (BIIB) stake by 6.1% in Q1 2026, selling an estimated $3.78M and leaving 318,745 shares worth $58.4M. The position accounts for 0.11% of the portfolio, ranked #208.

Man Group first reported a position in BIIB in Q1 2018 and has held it in 30 quarters since. The position peaked at $211M in Q4 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Man Group held 318,745 shares of Biogen worth $58.4M as of Q1 2026.
Man Group sold 20,539 Biogen shares in Q1 2026, an estimated $3.78M.
Biogen made up 0.11% of Man Group's portfolio in Q1 2026, its #208 holding.
Man Group first reported a position in Biogen in Q1 2018 and has held it in 30 quarters since.
Man Group's Biogen position peaked at $211M in Q4 2019.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.